12:00 AM
Jun 06, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Lytixar: Phase I/IIa data

A placebo-controlled, Hungarian Phase I/IIa trial showed that Lytixar was well tolerated, with negligible systemic uptake....

Read the full 57 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >